Table 1.
Patient, tumor, and treatment characteristics.
| Variables | IMRT n = 194 |
PBSPT n = 25 |
SMD | p-Value | |
|---|---|---|---|---|---|
| Sex | Male | 150 (77.3) | 21 (84.0) | 0.170 | 0.615 |
| Female | 44 (22.7) | 4 (16.0) | |||
| Age, years | 62.0 [56.0; 67.0] | 67.0 [61.0; 75.0] | 0.685 | 0.003 | |
| ECOG | 0–1 | 191 (98.5) | 23 (92.0) | 0.306 | 0.101 |
| Smoking history | Never smoker | 44 (22.7) | 2 (8.0) | 0.416 | 0.151 |
| Current or ex-smoker | 150 (77.3) | 23 (92.0) | |||
| Histology | Squamous cell carcinoma | 75 (38.7) | 15 (60.0) | 0.468 | 0.067 |
| Adenocarcinoma | 114 (58.8) | 9 (36.0) | |||
| Etc. | 5 (2.6) | 1 (4.0) | |||
| NOS | 3 | 1 | |||
| LCNEC | 2 | ||||
| EGFR mutant, n (%) | 37 (19.1) | 2 (8.0) | 0.328 | 0.266 | |
| ALK translocation, n (%) | 6 (3.1) | 0 (0.0) | 0.253 | 1.000 | |
| Clinical T stage | cT1–2 | 126 (64.9) | 15 (60.0) | 0.102 | 0.791 |
| cT3–4 | 68 (35.1) | 10 (40.0) | |||
| Clinical N stage | cN2 | 72 (26.8) | 13 (52.0) | 0.534 | 0.018 |
| cN3 | 142 (73.2) | 12 (48.0) | |||
| N3 involvement region | Contralateral mediastinum | 84 (43.3) | 5 (20.0) | 0.517 | 0.044 |
| Supraclavicular | 71 (36.6) | 9 (36.0) | 0.012 | 1.000 | |
| Overall stage | IIIA | 23 (11.9) | 9 (36.0) | 0.604 | 0.008 |
| IIIB | 138 (71.1) | 12 (48.0) | |||
| IIIC | 33 (17.0) | 4 (16.0) | |||
| Pre-treatment pulmonary function test | |||||
| FEV1, L | 2.50 (2.10; 3.06) | 2.35 (1.61; 2.81) | 0.487 | 0.040 | |
| FEV1, % | 84.0 (71.0; 95.0) | 72.0 (57.0; 88.0) | 0.420 | 0.042 | |
| FEV1 < 70% (moderate to severe) | 44 (22.7) | 10 (40.0) | 0.100 | ||
| FEV1 < 50% (severe) | 9 (4.6) | 5 (20.0) | 0.013 | ||
| DLco, % | 79.5 (66.0; 92.0) | 65.0 (51.0; 79.0) | 0.654 | 0.002 | |
| DLco < 60% (moderate to severe) | 30 (15.5) | 10 (40.0) | 0.006 | ||
| DLco < 40% (severe) | 2 (1.0) | 1 (4.0) | 0.306 | ||
Values are presented as number of patients (%) or median (interquartile range). Abbreviations: IMRT, intensity-modulated radiation therapy; PBSPT, pencil beam scanning proton therapy; SMD, standardized mean difference; SD, standard deviation; IQR, interquartile range; NOS, not otherwise specified; LCNEC, large cell neuroendocrine carcinoma; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; FEV1, forced expiratory volume in 1 s; DLco, diffusing capacity of the lung for carbon monoxide.